The European Medicines Agency (EMA) announced on Tuesday 04 May 2021 the launch of a real-time examination procedure for the candidate vaccine against Covid-19, developed by the Chinese biotechnology company Sinovac Biotech, on the basis of results preliminary.
Continuous review process launched in Europe for Chinese vaccine
Already used in several countries such as China, Indonesia, Brazil and Turkey, the vaccine against Covid-19 from Chinese biotechnology company Sinovac is now undergoing continuous review in Europe. This was announced by the European Medicines Agency on Tuesday, May 4, 2021. While its effectiveness rate varies between 51 and 82% depending on the studies, the European Union health authority specified that Data from this vaccine will be evaluated as and when they become available in the context of emergency authorization.
In a press release, the EMA explains that “ The decision of the CHMP (Committee for Medicinal Products for Human Use) to start the continuous review is based on preliminary results from laboratory studies (non-clinical data) and clinical studies. These studies suggest that the vaccine triggers the production of antibodies that target SARS-CoV-2, the virus that causes COVID-19, and may help protect against the disease.e ”. Therefore, the EMA will assess the data as soon as it becomes available to decide whether the benefits outweigh the risks. The exam will take place ” until sufficient evidence is available for an official marketing authorization application »She explains.
How does the vaccine work?
Also called Vero Cell, the Covid-19 vaccine candidate developed by Chinese biotechnology company Sinovac Biotech is an inactivated vaccine. This technology, already used in the manufacture of vaccines against influenza and polio, consists of inactivating the virus by means of a physicochemical process. In its press release, the European Medicines Agency explains: “ The vaccine contains SARS-CoV-2 which has been inactivated (killed) and cannot cause disease. The inactivated COVID-19 (Vero Cell) vaccine also contains an ‘adjuvant’, a substance that helps strengthen the immune response to the vaccine. “.
Besides, “ When a person receives the vaccine, their immune system recognizes the inactivated virus as foreign and makes antibodies against it. If the vaccinated person later comes into contact with SARS-CoV-2, the immune system will recognize the virus and be ready to defend the body against it. “.
